Search Results - Collaboration+Sought+%3e+Collaboration

605 Results

Sort By:

Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor. Description of Technology: T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha...

Published: 8/25/2025 | Inventor(s): James Kochenderfer, Lauren Cutmore

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections. Description of Technology: Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused...

Published: 8/21/2025 | Inventor(s): Scott Norberg, Clint Allen, Zulmarie Franco, Ke Bai

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof

Summary: The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP). Description of Technology: Recurrent...

Published: 8/21/2025 | Inventor(s): Scott Norberg, Clint Allen, Xiaolin Wu

Keywords(s):

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, Application > Diagnostics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Chimeric VLP vaccines to Prevent HTLV-1 Infection

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection. Description of Technology: There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult...

Published: 8/12/2025 | Inventor(s): Genoveffa Franchini, Sarkis Sarkis, Ramona Moles, Cynthia Masison, Massimiliano Bissa

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

A conserved viral peptide for use in cancer immunotherapy

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment. Description of Technology: Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic...

Published: 8/21/2025 | Inventor(s): Xin Wei Wang, Lichun Ma, Man Hsin Hung

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy

Summary: The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. Description of Technology: Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven...

Published: 8/21/2025 | Inventor(s): Jay Berzofsky, Shweta Tiwary

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling

This technology includes a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform...

Published: 7/15/2025 | Inventor(s): Anagha Rama Varma, Parnika Kant, Kaitlyn Sadtler, Parinaz Fathi, Nicole Morgan, Paniz Rezvan Sangsari, Madison Daminato

Keywords(s):

Category(s): Application > Diagnostics, Application > Medical Devices, Application > Research Materials, Application > Therapeutics, ResearchProducts > Human Cell Lines, ResearchProducts > Research Equipment, TherapeuticArea > Endocrinology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Synergistic Interactions for Improved Cancer Treatment

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer. Description of Technology: Immunotherapy has emerged as a promising treatment...

Published: 6/27/2025 | Inventor(s): Barbara Felber, George Pavlakis, Sevasti Karaliota, Dimitrios Stellas

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain

This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy...

Published: 6/11/2025 | Inventor(s): Young-Hwan Jung, Zhiwei Wen, Kenneth Jacobson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Neurology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

PET Imaging Agents for Fungal Infections

Available for licensing and commercial development are patent rights covering PET imaging agents, methods of their synthesis, and their uses in imaging specific fungal infections. Fungal infections remain a global health problem resulting in over 1.5 million annual deaths. Immunocompromised patients, especially those undergoing cancer treatments or...

Published: 8/13/2025 | Inventor(s): Dima Hammoud, Swati Shah, Peter Williamson, Rolf Swenson, Xiang Zhang, Falguni Bhattacharyya

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Collaboration Sought > Licensing

1 2 3 4 5 6 7 8 9 10 ...